Description | This product 87G7 is a receptor-blocking human monoclonal antibody. It retained potent in vitro neutralizing activity against SARS-CoV-2 variants including the Alpha, Beta, Gamma, Delta and Omicron VOCs. 87G7 exhibits potent neutralizing efficacy against Wuhan-Hu-1 S mediated cell entry. 87G7 could also protect mice and hamsters prophylactically against challenge with all current SARS-CoV-2 VOCs, and shows therapeutic activity against SARS-CoV-2 challenge in both animal models. |
Clonality | Monoclonal |
Host Species | Human |
Target Species | SARS-CoV-2 (Alpha, Beta, Gamma, Delta, Omicron BA.1 and BA.2) |
Immunogen | SARS-CoV-2 spike protein |
Epitope | An epitope containing residues Y421, L455, F456, F486 and Y489 of RBD domain. |
Isotype | IgG1 kappa |
Expression Species | HEK293F or CHO cell line |
Conjugation | Unconjugated |
Purity | >95% |
Endotoxin | <1 EU/mg |
Form | Liquid |
Purification | Protein A purified |
Sterility | 0.2 μM filtered |
Formulation | PBS, pH 7.4 |
Preservation | No preservatives |
Stabilizer | No stabilizers |
Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
Application | ELISA; BLI; Neut |
Application Notes | 87G7 was found to block the binding of recombinant S trimer to ACE2 by BLI and ELISA-based assay. ELISA: The antibody started at 10 μg/mL with a serial 1:5 dilution. Bio-layer interferometry (BLI): The biosensor tips were immersed into a well containing mAb (50 μg/mL) for 15 min. Live virus neutralization: 87G7 potently neutralized D614G (IC50: 5.7 ng/ml), Wuhan-Hu-1 (IC50: 5.4 ng/ml), Lambda and Mu variants (IC50s: 1.2 and 4.8 ng/ml, respectively),as well as Alpha, Beta, Gamma, Delta and Omicron (BA.1/BA.2) with IC50 values ranging from 3.1 to 12.5 ng/ml. |
ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
WB | Western Blot Protocol |
FC | Flow Cytometry Protocol |
Target | SARS-CoV-2 S1 |
Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
Research Area | Coronavirus Disease 2019 |
Related Disease | Coronavirus Disease 2019 |